Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first commercial viral vector Contract Development and Manufacturing Organisation (CDMO), today announces that it has entered into a ...

Accelerate CGT developement with strategic viral vector manufacturing and CDMO partnerships that balance quality, cost, and speed from bench to clinic.

Detailed price information for Oxford Biomedica Plc New (OXBDF) from The Globe and Mail including charting and trades.

SK pharmteco today announced a significant funding commitment to support strategic initiatives within its viral vector ...

RANCHO CORDOVA, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- SK pharmteco today announced the successful CGMP qualification of its manufacturing facility in Corbeil-Essonnes, France. This ...

PHILADELPHIA--(BUSINESS WIRE)--VintaBio, a biotech manufacturing technology company specializing in high-yield, high-purity viral vector production for reliable gene therapy access, will present ...

A global contract developer says it is among the first to offer a standardized approach to manufacturing adeno-associated viruses (AAVs) and lentiviruses (LVVs) for advanced therapies. AGC Biologics ...

The "Cell and Gene Therapy Manufacturing Market -- Growth, Share, Opportunities & Competitive Analysis, 2024 -- 2032" report has been added to the Credence Research Inc. offering. The global Cell and ...

Next step in a broader collaboration to support VVMF build viral vector manufacturing capabilities Oxford, UK – 18 March 2026 ...

Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first commercial viral vector Contract Development and Manufacturing Organisation (CDMO), today announces that it has ...

The SK pharmteco group is now offering a standardized viral vector and plasmid manufacturing process to a global audience. The global approach can help customers move to batches for clinical trials in ...